Comparative Pharmacology
Head-to-head clinical analysis: NAFCILLIN SODIUM versus VEETIDS 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAFCILLIN SODIUM versus VEETIDS 500.
NAFCILLIN SODIUM vs VEETIDS '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nafcillin exerts bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
VEETIDS '500' (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis. It has activity against both gram-positive and gram-negative bacteria.
1-2 g IV every 4 hours; or 1-2 g IM every 4-6 hours.
1 tablet (500 mg) orally twice daily for 7 days.
None Documented
None Documented
Approximately 0.5 hour (30 minutes) in adults with normal renal function; prolonged to 1-2 hours in neonates or severe renal impairment. Clinically relevant for dosing every 4-6 hours.
4-6 hours (prolonged in renal impairment; requires dose adjustment if CrCl <30 mL/min)
Primarily renal (30-40% unchanged) and hepatic/biliary elimination. Approximately 10-15% excreted in bile via feces.
Renal: 60-80% unchanged; biliary/fecal: 15-25% as metabolites
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic